AUTHORS
Reid W Merryman, MD, Joshua D. Brody, MD2, Robert Redd, MS3, Heather A. Walker, BS, MPH4, Jenna Mahns5, Samantha Normilus, BSN6, Siri Sagedahl, BA7, Ioulia Vogiatzi, PhD8, Mingzeng Zhang, MD, PhD9, Emily Sumpena, BA10, Weihsin Chuan11, Inhye E Ahn, MD12, Amy Bessnow, MD, MPH13, Jennifer R. Brown, MD, PhD14, Jennifer L. Crombie, MD15, Matthew S Davids, MD, MMSc16, David C Fisher, MD17, Cynthia K. Hahn, MD, PhD18, Eric Jacobsen, MD19, Caron Jacobson, MD, MMSc20, Austin I Kim, MD21, Ann LaCasce, MD, MMSc22, Oreofe Odejide, MD, MPH23, Erin Parry, MD, PhD24, David Qualls, MD25, Christine Ryan, MD26, Aswin Sekar, MD, PhD27, Hua-Jay Jeffery Cherng, MD28, Philippe Armand, MD29, Mark Murakami, MD30, Gottfried von Keudell, MD31
AFFILIATIONS
1 Dana-Farber Cancer Institute, Boston, United States
2 Icahn School of Medicine at Mount Sinai, New York, United States
3 Dana-Farber Cancer Institute, Boston, United States
4 Dana-Farber Cancer Institute, Boston, United States
5 Dana-Farber Cancer Institute, Boston, United States
6 Dana-Farber Cancer Institute, Boston, United States
7 Dana-Farber Cancer Institute, Boston, United States
8 Dana-Farber Cancer Institute, Boston, United States
9 Dana-Farber Cancer Institute, Boston, United States
10 Dana-Farber Cancer Institute, Boston, United States
11 Dana-Farber Cancer Institute, Boston, United States
12 Dana-Farber Cancer Institute, Boston, United States
13 Dana-Farber Cancer Institute, Boston, United States
14 Dana-Farber Cancer Institute, Boston, United States
15 Dana-Farber Cancer Institute, Boston, United States
16 Dana-Farber Cancer Institute, Boston, United States
17 Dana-Farber Cancer Institute, Boston, United States
18 Dana-Farber Cancer Institute, Boston, United States
19 Dana-Farber Cancer Institute, Boston, United States
20 Dana-Farber Cancer Institute, Boston, United States
21 Dana-Farber Cancer Institute, Boston, United States
22 Dana-Farber Cancer Institute, Boston, United States
23 Dana-Farber Cancer Institute, Boston, United States
24 Dana-Farber Cancer Institute, Boston, United States
25 Dana-Farber Cancer Institute, Boston, United States
26 Dana-Farber Cancer Institute, Boston, United States
27 Dana-Farber Cancer Institute, Boston, United States
28 Columbia University, New York, United States
29 Dana-Farber Cancer Institute, Boston, United States
30 Dana-Farber Cancer Institute, Boston, United States
31 Beth Israel Deaconess Medical Center, Boston, United States
ABSTRACT
Background: Patients (pts) with follicular lymphoma (FL) and marginal zone lymphoma (MZL) would benefit from novel chemotherapy-free frontline treatment options that are effective and well-tolerated. We hypothesized that pretreatment with 4 weekly doses of obinutuzumab (obin) followed by 12 cycles (Cs) of the CD3/CD20 bispecific antibody glofitamab (glofit) would be safe and induce durable remissions. Here we report additional follow-up for FL pts and initial results from an MZL cohort treated with this regimen (NCT05783596).
Methods: Eligibility criteria included previously untreated grade 1-3A FL or MZL (any subtype), age ≥ 18, stage II-IV, requirement for therapy based on modified GELF criteria, and ECOG PS 0-2. During C1, pts received obin on days -21, -14, -7, and 0 followed by glofit step-up dosing (2.5 mg C1D1, 10 mg C1D8, 30 mg C2D1). Glofit continued on D1 for C3-C12. Pts were admitted for observation for 24 hours after the first dose of glofit. Responses were evaluated based on Lugano 2014 criteria using PET-CT (or CT for MZL pts without FDG-avid disease).
Results: 47 pts were enrolled. In the FL cohort (n=35), the median age was 63 (42-78). At study entry, 30 pts (86%) had stage IV, 6 (17%) grade 3A FL, 9 (26%) bulky disease (≥7 cm), and 22 (63%) a FLIPI score of 3-5. In the MZL cohort (n=12), the median age was 70 (37-80) and MZL subtypes included disseminated (n=5), nodal (n=3), splenic (n=2), and extranodal (n=2). At study entry, 11 pts (92%) had stage IV disease. By MZL-IPI score, 7 patients (58%) were intermediate risk and 5 (42%) were high risk.
In the FL cohort, the best objective response rate (ORR) and CMR rate were 100% (95CI 90-100%) and 94% (95CI 81-99%), respectively. To date, 2 pts have progressed, both on-treatment, yielding an end-of-treatment (EOT) CMR rate of 94% (95CI 81-99%). One pt had an isolated progression of CD20-negative FL, treated with low-dose radiation. The other pt progressed at C7 with CD20+ diffuse large B-cell lymphoma and achieved a CMR with subsequent therapy. With a median follow-up of 17.9 months (m), the 18m progression-free survival (PFS) is 94% (95CI 87-100%).
In the MZL cohort, the best ORR and CMR were 100% (95CI 74-100) and 92% (62-100), respectively. To date, 2 pts have relapsed, both at the EOT, yielding an EOT CMR rate of 75% (95CI 47-91). Relapse biopsies revealed CD20-negative MZL in one pt (who remains on observation) and EBV-negative classic Hodgkin lymphoma in the other, which shared a TP53 nuclear staining pattern with the prior MZL, suggesting a clonal relationship (pt is in a CR following AVD treatment). With a median follow-up of 13.7m, the 12m PFS is 81% (95CI 61-100%). No pt has died in either cohort.
Cytokine release syndrome (CRS) occurred in 19 pts (41%) with higher rates of G2+ CRS observed in MZL pts (FL any grade 40%, max G1 37%, G2 0%, G3 3%; MZL any grade 41%, max G1 8%, G2 33%, G3 0%). No neurotoxicity was observed. Infections (related or unrelated) occurred in 20 pts (43%; max G1 11%, G2 28%, G3 4%), including in 13 FL pts (37%) and 7 MZL pts (58%). The most common infections were upper respiratory (n=9) and lung infections (n=3). Other common treatment-related adverse events (trAEs) were generally similar in FL and MZL pts and include infusion-related reactions (40%), neutropenia (40%), fatigue (36%), chills (26%), and cough (26%). Common G3+ trAEs include neutropenia (G3 15%, G4 6%) and ALT increased (6%). No pts discontinued treatment due to AEs.
Preliminary correlative studies revealed that, compared to FL pts, MZL pts at baseline exhibited increased circulating CD4+ T cells (p<0.01), with reduced cytotoxicity (granzyme B, p<0.05) and a trend toward increased exhaustion (TIM3) features in circulating CD8+ T cells. In both FL and MZL pts, obin pre-treatment depleted peripheral B cells while reducing regulatory T cells (CD4+FoxP3+CD127-), which may prime the circulating immune system for glofit. CRS onset corresponded with acute increases in markers of activation (CD69) and cytotoxicity (granzyme B) in CD8+ T cells in both MZL and FL pts.
Conclusion: Glofit and obin achieved very frequent CMRs in pts with high-tumor burden FL. In MZL, despite a cohort enriched for high-risk features, CMR rates were similarly high, though G2+ CRS was observed more frequently. In FL, early PFS outcomes compare favorably to historical chemoimmunotherapy benchmarks, suggesting that this approach warrants additional investigation.
DISCLOSURES
Reid W Merryman, MD: Abbvie - Honoraria; Genmab - Honoraria; Genentech/Roche - Research Funding; Merck - Research Funding; Genmab - Research Funding; Bristol-Myers Squibb - Research Funding; KITE - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Genmab - Consultancy (Includes expert testimony); Ipsen - Consultancy (Includes expert testimony); Abbvie - Consultancy (Includes expert testimony); Bristol-Myers Squibb - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony)